Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent~* Male or female aged 40 to 75 years~* Meeting specified contraception requirements~* 12-lead electrocardiogram with heart rate 50-90 beats per minute, QT interval corrected using Fridericia's formula (QTcF) ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no clinically significant abnormalities~* Capable of complying with all study restrictions and procedures, including ability to use the study nebulizer correctly.~* Body mass index (BMI) 18 to 35 kg/m2 and minimum weight 45 kg.~* COPD diagnosis with symptoms compatible with COPD for at least 1 year~* Clinically stable COPD in the previous 4 weeks~* Ability to perform acceptable and reproducible spirometry.~* Post-bronchodilator spirometry at screening must demonstrate FEV1/forced vital capacity (FVC) ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal~* Chest X-ray (posterior-anterior) at screening, or chest X-ray, magnetic resonance imaging (MRI) or computed tomography (CT) scan in the last 12 months, showing no abnormalities which are both clinically significant and unrelated to COPD.~* Meet the concomitant medication restrictions and be expected to do so for the rest of the study.~* Current and former smokers with a smoking history of ≥10 pack years.~* Capable of withdrawing long acting bronchodilators until the end of the treatment period, and short acting bronchodilators for 8 hours prior to administration of study medication.~Exclusion Criteria:~* A history of life-threatening COPD including Intensive Care Unit admission and requiring intubation.~* COPD exacerbation requiring oral steroids in the previous 3 months~* A history of one or more hospitalizations for COPD in the previous 6 months~* Lower respiratory tract infection treated with antibiotics in the previous 3 months~* Evidence of cor pulmonale or clinically significant pulmonary hypertension.~* Patients with a current diagnosis of asthma, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea, known alpha-1 antitrypsin deficiency or other active pulmonary diseases.~* Previous lung resection or lung reduction surgery.~* Oral therapies for COPD (e.g. oral steroids, theophylline, and roflumilast) in the previous 3 months and throughout the study.~* Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Visit 1) and remains stable during the trial.~* A history of, or reason to believe a subject has, drug or alcohol abuse in the previous 3 years.~* Received an experimental drug within 30 days or five half-lives of the first dose~* Prior exposure to RPL554.~* Women who are pregnant or breast-feeding.~* Patients with a history of current uncontrolled disease that the Investigator believes are clinically significant.~* myocardial infarction in the previous 6 month; congestive heart failure, a history of unstable or uncontrolled hypertension, or has been diagnosed with hypertension in last 3 months.~* Use of oral beta blockers.~* Major surgery (requiring general anesthesia) in the previous 6 weeks, lack of full recovery from surgery at screening, or planned surgery through the end of the study.~* History of malignancy of any organ system within 5 years, with the exception of localized skin cancers (basal or squamous cell).~* Clinically significant abnormal values for safety laboratory tests~* Significant non-compliance in previous investigational studies or with prescribed medications.~* Requirement for oxygen therapy, even on an occasional basis.~* Known hypersensitivity to RPL554 or its excipients/components.~* Abnormal clinically significant 12 lead Holter findings,~* Any other reason that the Investigator considers makes the subject unsuitable to participate.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 0.75 mg RPL554 (Type: EXPERIMENTAL): None
- 1.5 mg RPL554 (Type: EXPERIMENTAL): None
- 3 mg RPL554 (Type: EXPERIMENTAL): None
- 6 mg RPL554 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).